Abstract P3-15-05: Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy

Background: Docetaxel, paclitaxel, and (nab)-paclitaxel are taxanes used in treating breast cancer at various stages. While fairly well tolerated, they can cause distressing side effects. Both the prevalence and severity of muscle and joint symptoms (MJ long term follow-up will conclude in August 2010. Results: The average age of patients was 53 years. Disease status was classified as early for 50%, locally advanced for 35.34 %, and metastatic for 15.51% of patients. Overall 41.4% and 39.6% of patients reported muscle and joint pain, respectively, in their diaries on days 1 to 7. Muscle pain was most commonly reported in the legs, back, and arms and joint pain in the knees, ankles, and hips. The pain was most often described as aching, tiring, nagging, exhausting, and tender. The following scores are derived from a 10 cm visual analog scale. Of those who experienced pain in the seven days after treatment, the mean rating for pain at its worst was 5.15 and 5.02 for muscle and joint pain, respectively. Pain at its least had an average rating of 3.42 and 3.41 for muscle and joint pain, respectively. With respect to interference, patients who experienced pain had a mean score of 5.39, 4.86, 5.5, 4.12, 5.36, and 5.44 for interference with basic activities in daily life, mood, working or housework, relationships, sleeping and enjoyment of life, respectively. One, 3, 6, 9 and 12 months after taxane treatment ended, 27.2% (22/81), 31% (13/42), 45.5% (20/44), 37.2% (16/43), and 26.9% (7/26) reported muscle pain, respectively. Joint pain was reported by 26% (21/81), 38.1% (16/42), 43.2% (19/44), 48.8% (21/43) and 34.6% (9/26) of patients 1, 3, 6, 9 and 12 months following treatment, respectively. Data entry and analysis is ongoing and the final analysis will report on pain in relation to the taxane used, steroid tapering, role of anti-hormonal therapy, and effect of menopause on incidence of MJ70(24 Suppl):Abstract nr P3-15-05.